Globally, millions of people are affected by Alzheimer's disease, with around 120,000 individuals in Norway alone. Witnessing a loved one gradually decline because of this devastating condition can be ...
Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
Agilent Technologies Inc. today announced that Boehringer Ingelheim has been selected as the winner of Agilent's inaugural Instrument Trade?In Impact Award, recognizing exceptional sustainability ...
Globally, millions of people are affected by Alzheimer's disease, with around 120,000 individuals in Norway alone. Witnessing a loved one gradually ...
Guggenheim Securities Emerging Outlook: Biotech Summit 2026 February 12, 2026 12:30 PM ESTCompany ParticipantsR.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion ...
The FDA’s refusal to review Moderna’s mRNA-based flu vaccine is part of a larger communications crisis unfolding at the agency over the past nine months that has also ensnarled Sarepta, Capricor, ...
Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted ...
DiMe introduces core digital measures set to accelerate drug development for pediatric rare diseases
These open-access resources will accelerate the development of life-saving therapies, improve prioritization in drug pipelines, and reduce development costs BOSTON, Jan. 29, 2026 /PRNewswire/ -- The ...
Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Hosted on MSN
HC Wainwright says market remains unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 program
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list. TheFly reported on January 13 that H.C. Wainwright analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results